Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Marken Expands Kit-Building Operations in Singapore

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Singapore joins Marken’s other facilities around the globe.

Marken has announced that they have expanded their kit-building operations into Singapore due to a growing demand from its clients. The facility is fully operational and began shipping for its first client earlier this year.

The kit-building unit in Singapore is managed by a dedicated trained staff and is supported by the GMP operators and QA personnel who operate the depot facility.

The depot / kit facility is also adjacent to Marken’s Singapore distribution hub, located near the Chiangi airport. Marken staff can therefore receive drug product and kit materials at the depot, assemble and store kits, store drug product and distribute all clinical materials to investigator sites throughout Asia.

The addition of the Singapore site is part of an ongoing global expansion plan within Marken. With kit-building locations already operational in Hamburg, and now Singapore, Marken is also evaluating an additional kit-building facility in either Miami or Brazil in the coming months.

Marken currently produces 15,000 kits per month and distributes more than 350,000 kits annually to investigator sites around the world. Ample capacity is currently available, and more capacity will be added as client demand develops.

Wes Wheeler, Marken’s Chief Executive Officer, said, “We are pleased to be able to offer this expanded service to our clients in the APAC region. Our ability to assemble kits in Singapore gives us a solid platform in Asia and again enhances our portfolio of services to clients in the region. We look forward to serving more global clients with our other facilities as we continue to grow, both in the Asia region and around the world.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Marken Opens New Philadelphia Hub
Distribution of clinical trial supplies within all temperature ranges.
Saturday, May 16, 2015
Marken Announces Moscow Depot
Marken’s global depot network expands to seven.
Thursday, October 03, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!